In this study, we investigated the effect of (−)-epigallocatechin-3-gallate (EGCG) on cyclic nucleotide production and vasodilator-stimulated phosphoprotein (VASP) phosphorylation in collagen (10 μg/mL)-stimulated platelet aggregation. ]i mobilization and TXA2 production on collagen-induced platelet aggregation. Conclusions: These results strongly indicate that EGCG is a beneficial compound elevating cAMP level in collagen-platelet interaction, which may result in the prevention of platelet aggregationmediated thrombotic diseases.
Introduction
Platelet aggregation is absolutely essential for the formation of a haemostatic plug when normal blood vessels are injured; however, the interactions between platelets and collagen can also cause circulatory disorders, such as thrombosis, atherosclerosis, and myocardial infarction 1) . Accordingly, inhibition of the plate-loyl group at the 3' position of catechin, which is known to have anti-platelet [13] [14] [15] [16] , anti-oxidative 17) , anti-inflammatory 18) , anti-carcinogenic 19) , anti-hypertensive 20) , and various biological effects 21) . In addition, it is known that EGCG has anti-platelet activity by inhibiting p38 mitogen-activated protein kinase and extracellular signal-regulated kinase-1/2 13) and by reducing thrombin-induced [Ca 2＋ ]i increase via inhibition of Syk and Lyn activities 14) . EGCG has also been reported to inhibit collagen-induced PLC-r 2 activity and TXA2 production 15) ; however, Ca 2＋ -antagonistic intracellular molecules such as cAMP and cGMP were not determined in their previous reports [13] [14] [15] . In particular, it is known that EGCG has no effect on the elevation of cAMP in collagen-activated platelets 16) ; however, in the present study, we found that EGCG strongly stimulated the phosphorylation of VASP-Ser 157 via the cAMP/A-kinase pathway rather than the phosphorylation of VASP-Ser 239 by the cGMP/G-kinase pathway.
Materials and Methods

Materials
Collagen was obtained from the Chrono-Log Corporation (Havertown, PA, USA). Fura 2-AM, 8-bromoadenosine-3',5'-cyclic monophosphorothioate, Rp-isomer (Rp-8-Br-cAMPS), 9-(tetrahydro-2´-furyl)adenine (SQ22536), 1-ethyl-4-[(1-methylethylidene)hydrazino] 1H-pyrazolo [3,4-b] pyridine-5-carboxylic acid (Etazolate), (−)-epigallocatechin-3-gallate (EGCG), and other reagents were obtained from Sigma Chemical Corporation (St. Louis, MO, USA). cAMP, cGMP, and TXB2 enzyme immunoassay (EIA) kits were purchased from GE Healthcare (Buckinghamshire, UK).
Preparation of Washed Rat Platelets
Blood was collected from Sprague-Dawley rats (6-7 weeks old, male), and anti-coagulated with ACD solution (0.8% citric acid, 2.2% sodium citrate, 2.45% glucose). Platelet-rich plasma was centrifuged at 125×g for 10 min to remove red blood cells, and the platelets were washed twice with washing buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.36 mM NaH2PO4, 5.5 mM glucose, and 1 mM EDTA, pH 7.4). The washed platelets were then resuspended in suspension buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.36 mM NaH2PO4, 0.49 mM MgCl2, 5.5 mM glucose, 0.25% gelatin, pH 7.4) to a final concentration of 5×10 8 /mL. All of the above procedures were carried out at 25 ℃ to avoid platelet aggregation on cooling. The ethics committee let-collagen interaction might be a promising approach for the prevention of thrombosis. An important role in the mechanism by which collagen induces platelet aggregation is played by thromboxane A2 (TXA2) formation 2) , which also contributes to an increase in cytosolic free Ca 2＋ ([Ca 2＋ ]i). An increase in [Ca 2＋ ]i activates both the Ca 2＋ /calmodulin-dependent phosphorylation of myosin light chain and the diacylglycerol (DG)-dependent phosphorylation of pleckstrin to induce platelet aggregation 3, 4) . In addition, DG can be hydrolyzed by DG lipase to produce arachidonic acid (20:4), a precursor of TXA2, which is a potent platelet aggregation agent generated from 20:4 liberated when phosphatidylinositol 4, 5-bisphosphate (PIP2) is broken down by phospholipase C (PLC) in collagen-, thrombin-, and ADP-activated platelets [3] [4] [5] . Verapamil and theophylline have anti-platelet functions that elevate the adenosine 3',5'-cyclic monophosphate (cAMP) level, and then decrease [Ca 2＋ ]i, an essential factor for platelet aggregation. Vasodilators (such as molsidomine and nitroprusside) and guanosine 3',5'-cyclic monophosphate (cGMP) phosphodiesterase (PDE) inhibitors (such as zaprinast and erythro-9-[2-hydroxy-3-nonyl]adenine) elevate cGMP levels in platelets 5) . It is believed that cGMP is produced via the activation of guanylate cyclase in the presence or absence of nitric oxide (NO). NO, synthesized in platelets, decreases agonist-elevated [Ca 2＋ ]i 6) and has a role in inhibiting platelet activation 7) . Accordingly, from the above-mentioned reports, it can be seen that antiplatelet substances have activities to inhibit [Ca 2＋ ]i mobilization or TXA2 production, aggregation-inducing molecules, and increase the production of cAMP or cGMP, aggregation-inhibiting molecules. It is known that the effects of cAMP and cGMP on platelets are mediated via cAMP-and cGMP-dependent protein kinases (A-kinase, G-kinase), which phosphorylate substrate protein, vasodilator-stimulated phosphoprotein (VASP), involved in the platelet aggregation inhibitory pathway [8] [9] [10] . VASP is composed of 46 kDa-dephosphoprotein and 50 kDa-phosphoprotein 9) . If VASP is phosphorylated by A-kinase or G-kinase, phosphorylation of VASP (p-VASP) shifts from 46 kDa-dephosphoprotein to 50 kDa-phosphoprotein 8, 9) . Ser 157 at 50 kDa of VASP is phosphorylated by the cAMP/A-kinase pathway, whereas Ser 239 at 50 kDa of VASP is phosphorylated by the cGMP/G-kinase pathway 11, 12) ; therefore, phosphorylation of Ser 157 or Ser 239 at 50 kDa of VASP is a useful indicator for monitoring cAMP/A-kinase and cGMP/G-kinase pathways.
A major catechin analogue, (−)-epigallocatechin-3-gallate (EGCG, Fig. 1A) , from green tea has a gal-sensitive, so the tube containing the platelet-rich plasma was covered with aluminum foil during loading. The fura 2-loaded washed platelets were prepared using the procedure described above and platelets 10 8 / mL were preincubated for 3 min at 37 ℃ with various concentrations of EGCG in the presence of 2 mM CaCl2 and then stimulated with collagen (10 μg/mL) for 5 min for evaluation of [Ca 2＋ ]i. Fura 2 fluorescence was measured with a spectrofluorimeter (SFM 25; Bio-Teck Instrument, Italy) with an excitation wavelength that was changed every 0.5 sec from 340 to 380 nm; the emission wavelength was set at 510 nm. The [Ca 2＋ ]i values were calculated using the method of Schaeffer 22) .
Measurement of TXB2
Washed platelets (10 8 /mL) were preincubated with or without EGCG for 3 min in the presence of 2 for animal experiments of Inje University (Gimhae, Gyungnam, Korea) approved these animal experiments.
Measurement of Platelet Aggregation
Washed platelets (10 8 /mL) were preincubated for 3 min at 37 ℃ in the presence of 2 mM exogenous CaCl2 with or without EGCG and then stimulated with collagen (10 μg/mL) for 5 min. Aggregation was monitored using an aggregometer (Chrono-Log, Corp.) at a constant stirring speed of 1,000 rpm. Each aggregation rate was evaluated as an increase in light transmission. Suspension buffer was used as a reference. EGCG was dissolved in distilled water.
Determination of [Ca
2＋
]i Platelet-rich plasma was incubated with 5 μM fura 2-AM at 37 ℃ for 60 min. Fura 2-AM is light- Collagen (μg)
A C B was increased up to 81.5±2.4%; however, various concentrations of EGCG (1 to 50 μM) significantly reduced collagen-stimulated platelet aggregation in a dose-dependent manner (Fig. 1C) .
Effects of EGCG on Regulation of AggregationInducing Molecules, [Ca
2＋
]i and TXA2 As shown in Fig. 2A , when washed platelets (10 8 / mL) were stimulated by collagen (10 μg/mL), the level of [Ca 2＋ ]i increased from 48.6±9.2, the basal level, to 90.2±8.3 nM; however, this was significantly mM CaCl2, and activated for 5 min with collagen (10 μg/mL). The reactions were terminated by the addition of ice-cold EDTA (5 mM) and indomethacin (0.2 mM). The amount of TXB2, a stable metabolite of TXA2, was determined with Synergy HT Multi-Model Microplate Reader (BioTek Instruments, Winoosku, VT, USA) using a TXB2 EIA kit.
Measurement of cAMP and cGMP
Washed platelets (10 8 /mL) were preincubated for 3 min at 37 ℃ with various concentrations of EGCG or other agonists in the presence of 2 mM CaCl2, and then stimulated with collagen (10 μg/mL) for 5 min for platelet aggregation. The aggregation was terminated by the addition of 80% ice-cold ethanol. cAMP and cGMP were measured Synergy HT Multi-Model Microplate Reader (BioTek Instruments) using cAMP and cGMP EIA kits.
Western Blot for Analysis of VASP Phosphorylation
Various volumes of platelet lysates containing the same protein (15 μg) were used for analysis. Protein concentrations were measured using a BCA protein assay kit (Pierce Biotechnology, USA). An 8-10% SDS-PAGE was used for electrophoresis and a PVDF membrane was used for protein transfer from the gel. The dilutions for anti-VASP, anti-phosphor-VASP (Ser 157 ), and anti-phosphor-VASP (Ser 239 ), and antirabbit IgG-HRP were 1:1000, 1:1000, 1:1000, and 1:10000, respectively. The membranes were visualized using enhanced chemiluminescence (ECL). Blots were analyzed using Quantity One, Ver. 4.5 (Bio-Rad, Hercules, CA, USA).
Statistical Analysis
The experimental results are expressed as the means±S.E.M. and are accompanied by the number of observations. Data were assessed by analysis of variance (ANOVA). If this analysis indicated significant differences among the group means, then each group was compared by the Newman-Keuls method. P ＜ 0.05 was considered significant.
Results
Effects of EGCG on Collagen-Induced Platelet Aggregation
The concentration of collagen-induced maximal platelet aggregation was approximately 10 μg/mL (Fig. 1B) 
23)
; therefore, 10 μg collagen/mL was used as the platelet agonist in this study. When washed platelets (10 8 /mL) were activated with 10 μg collagen/mL in the presence of 2 mM CaCl2, the aggregation rate ]i was determined as described in "Materials and Methods". (B) Effects of EGCG on the production of TXB2 stimulated by collagen. Washed platelets (10 8 /mL) were preincubated with EGCG for 3 min in the presence of 2 mM CaCl2, and then stimulated with collagen (10 μg/mL). TXB2 was determined as described in "Materials and Methods". The content of TXB2 was measured using a TXB2 EIA kit. Data are expressed as the means±S.E.M. (n = 4).
reduced by various concentrations (1 to 50 μM) of EGCG in a dose-dependent manner (83.5% inhibition at 50 μM). We next determined whether EGCG blocks the production of TXA2 by collagen stimulation. The TXA2 (determined as TXB2) level in intact platelets was 4.0±0.1 ng/10 8 platelets, and this was markedly increased to 356.1±46.9 ng/10 8 platelets in collagen-stimulated platelets (Fig. 2B) ; however, EGCG potently reduced the production of TXA2 to 37.3±0.4 ng/10 8 platelets (89.5% inhibition at 50 μM). Because collagen-produced TXA2 resulted from Ca 2＋ -dependent PLC activation, it is suggested that the inhibition of TXA2 production ( ]i and TXA2 to inhibit platelet aggregation 24) ; therefore, we next investigated whether EGCG up-regulates the cellular level of cAMP or cGMP.
Effects of EGCG on Production of cGMP and cAMP, Aggregation-Inhibiting Molecules
Collagen decreased intracellular cGMP from 1.40±0.15 pmoL/10 8 platelets (basal level) to 1.21± 0.15 pmoL/10 8 platelets in washed platelets ( Table 1) . When the platelets were incubated in the presence of both EGCG and collagen, cGMP by EGCG did not increase in a dose-dependent manner (Fig. 3A) . The cGMP level (1.43±0.04 pmoL/10 8 platelets) in the presence of both EGCG (50 μM) and collagen (10 μg/mL) increased to 18.2 % as compared with that (1.21±0.15 pmoL/10 8 platelets) in the presence of collagen (10 μg/mL) alone ( Table 1) .
Collagen decreased intracellular cAMP from 3.89±0.18 pmoL/10 8 platelets (basal level) to 3.44± 0.43 pmoL/10 8 platelets in washed platelets (Table 1) ; however, when the platelets were incubated in the presence of both EGCG and collagen, cAMP by EGCG increased in a dose-dependent manner (Fig. 3B) . The cAMP level (6.60±0.04 pmoL/10 8 platelets) in the Data were from Fig. 3. 1) , 2), and 5) changes to base; 3), 4), and 6) changes to collagen. Washed platelets (10 8 /mL) were preincubated with or without EGCG for 3 min in the presence of 2 mM CaCl2 and then stimulated with collagen (10 μg/mL) for 5 min at 37 ℃. The reactions were terminated by adding 80% ice-cold ethanol. cGMP contents were measured using EIA kits. Data are expressed as the means±S.E.M. (n = 4). (Fig. 4A lane 1, 2) . Collagen (10 μg/mL) increased p-VASP (Ser 157 and Ser 239 ) at 50 kDa phosphoprotein of VASP ( Fig. 4A lane 2) . It is known that thrombin and collagen, agonists of platelets, are involved in a feedback inhibition by elevating p-VASP (Ser 157 and Ser 239 ) 25) . EGCG itself stimulated the shift from 46 kDa dephosphoprotein of VASP to 50 kDa phosphoprotein of VASP, and markedly increased the p-VASP (Ser 157 ) only of VASP-50 kDa, which is observed in collagen-induced platelet aggrepresence of both EGCG (50 μM) and collagen (10 μg/mL) increased to 91.9% as compared with that (3.44±0.43 pmoL/10 8 platelets) in the presence of collagen (10 μg/mL) alone ( (Fig. 4B, D) . This suggests that EGCG strongly phosphorylates VASP (Ser 157 ), indicating the relation to A-kinase activation by EGCG-elevated cAMP. The band density (18050 density/mm 2 ) of p-VASP (Ser 239 ) by both EGCG and collagen was increased to 5.5% as compared with that (17188 density/mm 2 ) by collagen (Fig. 4C, D) . The phosphorylation of VASP (Ser 239 ) by EGCG is much slighter than p-VASP (Ser 157 ) (Fig. 4A lane 3, 4, C and  D) . This suggests that EGCG slightly phosphorylates VASP (Ser 239 ), indicating a relation to G-kinase activation of cGMP elevated slightly by EGCG.
Effects of EGCG on cAMP Production and VASP Phosphorylation in the Presence of Adenylate Cyclase Inhibitor, SQ22536
The cAMP level is regulated by adenylate cyclase, cAMP-specific phosphodiesterase (PDE4), cGMPstimulated phosphodiesterase (PDE2) and cGMPinhibited phosphodiesterase (PDE3) in platelets 26) . Because EGCG hardly affected cGMP production in both resting and collagen-stimulated platelets (Fig. 3A) , it is inferred that EGCG-elevated cAMP was not regulated by the inhibition of PDE2 hydrolyzing both cAMP and cGMP, and PDE3 hydrolyzing cAMP rather than cGMP. Accordingly, we set out to investigate in this study whether the EGCG-mediated cAMP level was regulated by enzymes of adenylate cyclase or PDE4. For the first time, we used SQ22536, an adenylate cyclase inhibitor. As a result, the EGCGincreased cAMP level (6.6±0.1 pmoL/10 8 platelets) was reduced in the presence of SQ22536 (10 μM) to 5.3±0.1 pmoL/10 8 platelets (Fig. 5A) . This suggests that EGCG-elevated cAMP (Fig. 3B) /mL) were preincubated with or without EGCG or SQ22536 for 3 min in the presence of 2 mM CaCl2 and then stimulated with collagen (10 μg/mL) for 5 min at 37℃ in an aggregometer. The reactions were terminated by adding 80% ice-cold ethanol. cAMP contents were measured using EIA kits. Data are expressed as the means±S.E.M. (n = 4). 
of both etazolate and EGCG, the cAMP level was increased up to 6.2±0.6 pmoL/10 8 platelets (Fig. 7) . This cAMP level (6.2±0.6 pmoL/10 8 platelets), however, was not synergistically increased as compared with that (6.6±0.1 pmoL/10 8 platelets) increased by EGCG in collagen-stimulated platelet aggregation. These results suggest that EGCG-activated cAMP enhancement (Fig. 3B, 7) is not mediated by the inhibition of cAMP-specific phosphodiesterase, PDE4.
Discussion
Catechins that have an anti-inflammatory effect are known to have anti-platelet function by inhibiting the liberation of TXA2 precursor 20:4 out of platelet membrane phospholipids and TXA2 synthase activity in collagen-activated platelets 13, 27, 28) . EGCG has been reported to inhibit collagen-activated Ca 2＋ -dependent PLC-γ2 and TXA2 production 13) . Since EGCG inhibited [Ca 2＋ ]I mobilization ( Fig. 2A) and TXA2 production (Fig. 2B) , but increased cAMP production (Fig. 3B, Table 1 ), as in previous reports 13, 27, 28) , this suggested that EGCG-elevated Ca 2＋ -antagonistic cAMP (Fig. 3B) may be involved in the inhibition of 20:4 liberation and TXA2 production by suppressing [Ca 2＋ ]I mobilization and Ca
2＋
-dependent PLC-γ2 activity. TXA2 is produced via cyclooxygenase-1 (COX-1) and the TXA2 synthase (TXAS) pathway from 20:4. In our other experiments, EGCG inhibited microsomal COX-1 activity to 91% as compared with that (1.4 nmoL/protein-mg/min) of the control, and inhibited microsomal TXAS activity to 20% as compared with the control (0.17 nmoL/protein-mg/min) (data not shown). It is thought that EGCG has multiple actions that reduce [Ca 2＋ ]i mobilization and TXA2 production-associated enzyme (COX-1, TXAS) activities to inhibit TXA2 production, and 20:4 is metabolized to prostaglandin E2, an inflammatory mediator, tion by cAMP is known to occur via the activation of A-kinase which phosphorylates VASP (Ser 157 ) 12, 26) in platelet aggregation; therefore, because the inhibition of A-kinase activation and VASP (Ser 157 ) phosphorylation induced platelet aggregation, we investigated whether EGCG affects collagen-stimulated platelet aggregation and VASP (Ser 157 ) phosphorylation in the presence of A-kinase inhibitor, Rp-8-Br-cAMPS.
As shown in Fig. 6A , in the presence of both Rp-8-Br-cAMPS and EGCG, the degree of collageninduced platelet aggregation (58.0±2.0%) was higher than that (18.0±3.0%) in the presence of EGCG alone. The band density (Fig. 6B lane 2, Table 4 ) of p-VASP (Ser 157 ) phosphorylated by both collagen and EGCG in the presence of Rp-8-Br-cAMPS was decreased to 76.1 % as compared with that ( Fig. 6B  lane 1, Table 4 ) in the absence of Rp-8-Br-cAMPS. These results reflect that the inhibitory effect of EGCG on collagen-induced platelet aggregation is involved in the phosphorylation of VASP (Ser 157 ) by the cAMP/A-kinase pathway.
Effects of EGCG on cAMP Production in the Presence of PDE4 Inhibitor Etazolate
As shown in Fig. 7 , when washed platelets were stimulated by collagen in the presence of etazolate alone (20 μM), the cAMP level was increased significantly from 3.5±0.3 pmoL/10 8 platelets to 5.3±0.5 pmoL/10 8 platelets. On the other hand, when washed platelets were stimulated by collagen in the presence Data are calculated from Table 2 . 1) change to collagen; 2) change to collagen plus EGCG. lated platelets ( Table 1) . The ratio of cAMP to cGMP was increased up to 64.3% in the presence of both collagen and EGCG as compared with that (2.8) in the absence of EGCG ( Table 1) . This suggests that EGCG directly produced cAMP and used it to decrease [Ca 2＋ ]i, an essential molecule for TXA2 production. cAMP and cGMP are involved in the inhibition of platelet aggregation by phosphorylating IP3 receptor or VASP via the A-kinase or G-kinase pathway. IP3 receptor phosphorylation is involved in the inhibition of [Ca 2＋ ]i mobilization 30, 31) , and VASP phosphorylation is known to regulate VASP affinity for platelet filamentous actin 32) . In the present study, it is unknown whether the inhibitory effect of [Ca 2＋ ]i by EGCG is due to the phosphorylation of IP3 receptor by cAMP or cGMP. In intact and collagen-activated platelets, EGCG phosphorylated A-kinase substrate VASP (Ser 157 ) markedly, but did not phosphoryby cyclooxygenase-2 (COX-2). Because it was observed in our other results that EGCG inhibits TXA2 production (Fig. 2B) and microsomal COX-1 (data not shown), it is clear that EGCG has an anti-inflammatory effect by inhibiting COX-2 activity, in the same way as EGCG has an anti-prostate carcinogenic effect by inhibiting COX-2 activity 29) . Because both platelet aggregation and inflammation are the cause of atherosclerosis, it is thought that EGCG could contribute to the treatment of cardiovascular disease.
Agonist-mobilized [Ca 2＋ ]i is decreased by cyclic nucleotides (cAMP and cGMP), and their receptors A-kinase and G-kinase are key modulators controlling platelet inhibition 24, 26) . EGCG (50 μM) significantly increased cAMP rather than cGMP in intact and collagen-induced platelet aggregation ( Table 1) . EGCG itself increased up to 46.4% the ratio of cAMP to cGMP from 2.8, the basal ratio, to 4.1 in unstimu- is 0.06 μM (60 pmoL/mL) 35) ; therefore, EGCG-elevated cAMP (Table 1, Fig. 3B) is not due to the inhibition of PDE3.
The next question therefore concerns the mechanism by which EGCG up-regulated the intracellular cAMP level. To solve this question, we used SQ22536 as an adenylate cyclase inhibitor and etazolate as a PDE4 inhibitor. The EGCG-elevated cAMP level was decreased by SQ22536 (Fig. 5A) , which results from inhibition of adenylate cyclase by SQ22536. Because SQ22536 decreased cAMP production, the phosphorylation of VASP (Ser 157 ) in the presence of EGCG was inhibited by SQ22536 (Fig. 5B) . These results suggest that EGCG produced cAMP from ATP by activating adenylate cyclase, and phosphorylated VASP (Ser 157 )-50 kDa by activating A-kinase to inhibit collageninduced platelet aggregation. Otherwise, p-VASP (Ser 157 ) phosphorylated by both EGCG and collagen would not be inhibited in the presence of Rp-8-BrcAMPS, an A-kinase inhibitor (Fig. 6, Table 4 ). On the other hand, even though PDE4 inhibitor etazolate increased cAMP in the presence of collagen, it did not increase cAMP in the presence of both EGCG and collagen (Fig. 7) . This means that EGCG-elevated cAMP is not due to the inhibition of PDE4 by EGCG.
Nakagawa et al. reported that human plasma EGCG concentrations before administration were all below the detection limit (＜2 pmoL/mL), but 90 min after, they were significantly and dose-dependlate G-kinase substrate VASP (Ser 239 ) (Fig. 4A) . These results are in accord with the result that EGCG markedly enhanced cAMP rather than cGMP in intact and collagen-stimulated platelets ( Table 1) . Eigenthaler et al. 33) reported that a small elevation in cAMP is enough to activate most A-kinase, whereas even several fold elevation of the cGMP level may stimulate only a small fraction of total G-kinase. This previous report 33) Fig. 4A, D) . In addition, EGCG-phosphorylated VASP-Ser 157 was inhibited by Rp-8-Br-cAMPS, an A-kinase inhibitor, which suggests that EGCG phosphorylates VASP-Ser 157 via both cAMP production and A-kinase activation. Sudo et al. 34) , using cilostazole, reported a similar result to our finding, and suggested that its antiplatelet effect is mediated through an increase of the cAMP level, A-kinase activity, and VASP phosphorylation. The levels of intracellular cAMP and cGMP are regulated by the balance between cyclic nucleotide-producing enzymes, adenylate/guanylate cyclases, and hydrolyzing enzymes, cAMP/cGMP PDEs. If EGCG inhibited the activity of PDE2 to produce cAMP and cGMP in intact and collagen-stimulated platelets, because PDE2 hydrolyzes both cAMP and cGMP 26) , EGCG would increase the level of cAMP and cGMP in intact and collagen-stimulated platelets; however, EGCG markedly increased the cAMP level only, and hardly increased the cGMP level ( Table 1 ). In particular, since EGCG did not increase but decreased cGMP production in intact platelets (Table 1), even though the cGMP level (1.43±0.04 pmoL/10 8 platelets) was increased to 18.2% in the presence of both collagen and EGCG as compared with that (1.21±0.15 pmoL/10 8 platelets) in the absence of EGCG (Table 1) , it is thought that EGCG-elevated cAMP (Fig. 3B) is not due to the regulation of cGMP-stimulated PDE2, cGMP-inhibited PDE3, and cGMP-binding-cGMPspecific PDE5. EGCG increased cGMP to about 0.22 pmoL/10 8 platelets as compared with that (1.21±0.15 pmoL/10 8 platelets) in the presence of collagen (10 μg/mL) (Table 1, Fig. 3A) . This increased cGMP level (0.22 pmoL/10 8 platelets) is not sufficient to inhibit PDE3 to increase cAMP, since it is known that Ki for cGMP inhibition of cAMP hydrolysis by PDE3 Fig. 7 . Effects of EGCG with etazolate, cAMP-specific phosphodiesterase inhibitor, on cAMP production in collagen-stimulated platelets. Washed platelets (10 8 /mL) were preincubated with or without etazolate or EGCG for 3 min in the presence of 2 mM CaCl2 and then stimulated with collagen (10 μg/mL) for 5 min at 37 ℃. The reactions were terminated by adding 80% ice-cold ethanol. cAMP contents were measured using EIA kits. Data are expressed as the means±S.E.M. (n = 4). ently increased to 657, 4300, and 4410 pmoL EGCG/ mL, in subjects who received 3, 5, and 7 capsules, respectively (corresponding to 225, 375, and 525 mg EGCG, respectively). EGCG levels detected in plasma corresponded to 0.2-2.0% of the ingested amount 36) . In the present study, although it is unknown whether 46-460 μg, corresponding to 0.2-2.0% of EGCG (MW. 458.37) 50 μM (23 mg) having anti-platelet activities, has clinic anti-platelet activity in vivo, which should be studied in the future, and if it has a dietary effect, it could be used to evaluate the anti-platelet effects of EGCG.
In conclusion, the most important result of this study is that EGCG significantly inhibits the level of ) through A-kinase activation to inhibit collagen-induced platelet aggregation. Therefore, these results suggest that EGCG is a physiologically effective negative feedback regulator during platelet aggregation, a cause of thrombosis, atherosclerosis, and myocardial infarction.
